Drugs / TDI01
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT06102083 | Nov 2023 → Aug 2025 | idiopathic pulmonary fibrosis | Beijing Tide Pharmaceutical Co., Ltd | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07464912 | Dec 2025 → Jul 2029 expected | idiopathic pulmonary fibrosis | Beijing Tide Pharmaceutical Co., Ltd | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT06169722 Comparator | Feb 2024 → Feb 2026 overdue | chronic graft versus host disease | Beijing Tide Pharmaceutical Co., Ltd | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-10-16 | Beijing Tide Pharmaceutical Co., Ltd | Regulatory 北京泰德制药 I 类新药「TDI01」获批抗新冠肺炎临床试验 tidepharm.com ↗
2022年9月23日，中国生物制药宣布，集团附属公司北京泰德制药股份有限公司自主研发的 I 类创新药「TDI01」已于2022年9月23日获得中国国家药品监督管理局批准开展新型冠状病毒肺炎的临床试验。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-10-16 | Beijing Tide Pharmaceutical Co., Ltd | 北京泰德制药 I 类新药「TDI01」获批抗新冠肺炎临床试验 tidepharm.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TDI01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06169722 ↗ |
| Route | Oral | “200mg or 400mg oral once a day” NCT06169722 ↗ |